Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of astaxanthin in 80 moderate to severe knee osteoarthritis patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either astaxanthin 12 mg capsule daily or placebo capsule identical to astaxanthin daily for 8 weeks. Evaluation of pain, stiffness and improvement of physical function will be measured by WOMAC index before and after intervention. Inflammatory markers serum IL-6 and hsCRP will be measured before and after intervention. Astaxanthin related adverse events will be identified. Study outcome will establish safety and efficacy of astaxanthin in knee osteoarthritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Criteria

Inclusion Criteria:

• Patients with knee pain

• Radiographic evidence of moderate to severe knee osteoarthritis

• Age 40 years or older

• Both male and female

Exclusion Criteria:

• Prior history of knee trauma or surgery

• Previously diagnosed of systemic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease

• Known allergy to fish or astaxanthin

• Currently taking immunosuppressant

• Pregnant and nursing mother

• Patients unwilling to participate or unwilling to give written consent